Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00412 ...
Drug Name Rosiglitazone
Molecular Weight 357.427
Molecular Formula C18H19N3O3S
CAS Number 122320-73-4
SMILES CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
External Links
DRUGBANK DB00412
PubChem Compound 77999
PDR 175
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 2.4 - 2.4 - DRUGBANK
Melting Point 122.5 ℃ 122-123 ℃ DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 99.0 % 99.0 % PO, oral; DRUGBANK
Bioavailability 99.0 % 99.0 % The Pharmacological Basis of Therapeutics
C Max 598.0 ng/ml 598±117 ng/ml Oral single dose; The Pharmacological Basis of Therapeutics
T Max 1.0 h 1 h PO, oral; DRUGBANK
T Max 2.8 h 2.75 h PO, oral; food; food ↑ ; DRUGBANK
T Max 1.0 h 1.0 h Oral single dose; The Pharmacological Basis of Therapeutics
Clearance 3.0 L/h 3.03±0.87 L/h Total clearance; PO, oral; fasting; DRUGBANK
Clearance 2.9 L/h 2.89±0.71 L/h Total clearance; PO, oral; fasting; DRUGBANK
Clearance 2.9 L/h 2.85±0.69 L/h Total clearance; PO, oral; fasting; DRUGBANK
Clearance 3.0 L/h 2.97±0.81 L/h Total clearance; PO, oral; food; DRUGBANK
Clearance 3.2 L/h 3.15 L/h Average clearance; pediatric patients; DRUGBANK
Clearance 0.0408 L/h/kg 0.68±0.16 ml/min/kg apparent clearance; type 2 diabetes; Male, men;  Female, women; The Pharmacological Basis of Therapeutics
Clearance 0.0294 L/h/kg 0.49 ml/min/kg Average clearance; hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Clearance 0.0390 L/h/kg 0.65 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 17.6 L 17.6 L PO, oral; DRUGBANK
Volume of Distribution 13.5 L 13.5 L pediatric patients; DRUGBANK
Volume of Distribution 0.25 L/kg 0.25±0.08 L/kg Apparent volume of distribution; type 2 diabetes; Male, men;  Female, women; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.21 L/kg 0.21 L/kg Average volume of distribution; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.20 L/kg 0.2 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 3.5 h 3-4 h Oral single dose; dose → ; DRUGBANK
Half-life 3.5 h 3-4 h PO, oral; chronic liver disease ↑ ; The Pharmacological Basis of Therapeutics
Half-life 3.9 h 3.9 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 64.0 % ~64 % Urinary excretion; PO, oral; intravenous injection, IV; DRUGBANK
Eliminate Route 23.0 % ~23 % Faeces excretion; PO, oral; intravenous injection, IV; DRUGBANK
Eliminate Route 0 % ~0 % Urinary excretion; type 2 diabetes; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 99.8 % 99.8 % plasma proteins; DRUGBANK
Protein Binding 99.8 % 99.8 % type 2 diabetes; human, homo sapiens; hepatopathy，LD ↓ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 8.0 mg/day 8 mg/day PO, oral Avandia rosiglitazone maleate PDR
Max dose for adolescents 8.0 mg/day 8 mg/day PO, oral Avandia rosiglitazone maleate PDR
Max dose for adults 8.0 mg/day 8 mg/day PO, oral Avandia rosiglitazone maleate PDR
Max dose for geriatric 8.0 mg/day 8 mg/day PO, oral Avandia rosiglitazone maleate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1